Neuphoria Therapeutics (NEUP) Non-Current Assets (2021 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Non-Current Assets of $13.2 million for Q1 2026, down 3.46% year-over-year from $13.6 million in Q1 2025, and little changed quarter-over-quarter from $13.2 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Non-Current Assets (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Non-Current Assets for 6 consecutive years, with $13.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 3.46% year-over-year to $13.2 million; the TTM figure through Mar 2026 stood at $53.3 million (down 5.38% YoY), while the FY2025 annual figure was $13.5 million, down 6.27% from the prior year.
- Non-Current Assets steadied at $13.2 million in Q1 2026 per NEUP's latest filing, from $13.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $16.8 million in Q2 2022 and bottomed at $13.2 million in Q1 2026.
- Historically, Non-Current Assets has averaged $14.2 million across 5 years, with a median of $13.7 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets declined 9.04% — and 2026, when it declined 3.46%.
- Neuphoria Therapeutics' Non-Current Assets stood at $16.8 million in 2022, then declined by 9.04% to $15.3 million in 2023, then slipped by 10.07% to $13.8 million in 2024, then retreated by 4.05% to $13.2 million in 2025, then dropped by 0.45% to $13.2 million in 2026.
- Business Quant data shows NEUP's Non-Current Assets at $13.2 million in Q1 2026, $13.2 million in Q4 2025, and $13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 18.06 Bn |
| 10 | Neuphoria Therapeutics | 21.64 Mn | 2.20 Mn | - | 13.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.15 Mn |
| Dec 31, 2025 | 13.21 Mn |
| Sep 30, 2025 | 13.39 Mn |
| Jun 30, 2025 | 13.55 Mn |
| Mar 31, 2025 | 13.62 Mn |
| Dec 31, 2024 | 13.77 Mn |
| Sep 30, 2024 | 14.49 Mn |
| Jun 30, 2024 | 14.46 Mn |
| Jun 30, 2023 | 15.31 Mn |
| Jun 30, 2022 | 16.83 Mn |
| Jun 30, 2021 | 17.97 Mn |